Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs BIO-TECHNE Corp — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while BIO-TECHNE Corp trades at $71.44 (market cap $11.11B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3.6× BIO-TECHNE Corp's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TECH | |
|---|---|---|
Market Cap | $39.89B | $11.11B |
Sector | Health | Health |
52-Week High | $491.22 | $71.38 |
52-Week Low | $278.09 | $43.31 |
Enterprise Value | $38.15B | $11.19B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Bio-Techne (TECH) trades at $71.30, up 0.21% today, near the $73.00 acquisition offer from Merck KGaA announced June 25, 2026. The stock shows bullish technical signals with moving averages supporting upside, while fundamentals reveal high valuation multiples (P/E 101.84) amid declining net margins (6.01% in 2025). Recent earnings were mixed with one beat and two misses in the last four quarters. Cash flow improved in 2026 projections, and the balance sheet remains solid with $152.86M cash.
The pending acquisition at $73.00 per share limits near-term upside but provides a floor. Risks include shareholder litigation questioning the deal's fairness and execution volatility. Analyst consensus is evenly split between Buy and Hold, with the price target slightly below current levels. The primary opportunity is the acquisition premium, while fundamental weakness in profitability poses a risk if the deal falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
